Inventor · disambiguated record
Clark Pan
Also filed as: PAN CLARK · PAN CLARK Q · PAN CLARK QUN
56 granted patents·34 pending applications·585 citations·filing 1996–2025
99Inventor score
Files withGENZYME CORP38BAYER PHARMACEUTICALS CORP10BAYER HEALTHCARE LLC8SHIRE HUMAN GENETIC THERAPIES6TAKEDA PHARMACEUTICALS CO6
Top patents by PatentIndex Score
90 records- 0197US9790268B2Fc containing polypeptides with altered glycosylation and reduced effector functionGENZYME CORP·Filed 2014·Granted Oct 17, 2017·29 cites·39 claims
- 0296US11130816B2Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2019·Granted Sep 28, 2021·6 cites·20 claims
- 0396US10836813B2Fc containing polypeptides with altered glycosylation and reduced effector functionGENZYME CORP·Filed 2017·Granted Nov 17, 2020·11 cites·23 claims
- 0496US7632921B2Site-directed modification of FVIIIBAYER HEALTHCARE LLC·Filed 2005·Granted Dec 15, 2009·68 cites·22 claims
- 0595US12110338B2Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2021·Granted Oct 8, 2024·2 cites·29 claims
- 0695US11807690B2Hyperglycosylated binding polypeptidesGENZYME CORP·Filed 2019·Granted Nov 7, 2023·4 cites·17 claims
- 0795US10995148B2Site-specific glycoengineering of targeting moietiesGENZYME CORP·Filed 2015·Granted May 4, 2021·8 cites·39 claims
- 0894US10494439B2Hyperglycosylated binding polypeptidesGENZYME CORP·Filed 2017·Granted Dec 3, 2019·9 cites·19 claims
- 0994US9701753B2Hyperglycosylated binding polypeptidesGENZYME CORP·Filed 2014·Granted Jul 11, 2017·16 cites·25 claims
- 1094US9580511B2Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2014·Granted Feb 28, 2017·17 cites·47 claims
- 1194US7041646B2Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonistsBAYER PHARMACEUTICALS CORP·Filed 2003·Granted May 9, 2006·43 cites·3 claims
- 1293US11325971B2scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificityGENZYME CORP·Filed 2019·Granted May 10, 2022·4 cites·15 claims
- 1393US10214589B2Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2017·Granted Feb 26, 2019·9 cites·18 claims
- 1493US7407785B2Human DNase I hyperactive variantsGENENTECH INC·Filed 2004·Granted Aug 5, 2008·34 cites·5 claims
- 1592US11976112B2scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificityGENZYME CORP·Filed 2022·Granted May 7, 2024·1 cites·8 claims
- 1692US11279725B2Oligosaccharide-protein conjugatesGENZYME CORP·Filed 2019·Granted Mar 22, 2022·6 cites·19 claims
- 1792US11186638B2Anti-αβTCR antibodyGENZYME CORP·Filed 2018·Granted Nov 30, 2021·10 cites·11 claims
- 1892US10308917B2Nucleotide sequences encoding VEGF antagonist compositions of FLT-1 and uses thereofGENZYME CORP·Filed 2016·Granted Jun 4, 2019·7 cites·13 claims
- 1992US6864069B2Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of useBAYER PHARMACEUTICALS CORP·Filed 2002·Granted Mar 8, 2005·34 cites·3 claims
- 2092US6391607B1Human DNase I hyperactive variantsGENENTECH INC·Filed 1996·Granted May 21, 2002·74 cites·10 claims
- 2191US7091323B2Human TIMP-1 antibodiesBAYER AG·Filed 2002·Granted Aug 15, 2006·51 cites·12 claims
- 2290US7432364B2Human TIMP-1 antibodiesBAYER HEALTHCARE LLC·Filed 2006·Granted Oct 7, 2008·18 cites·20 claims
- 2390US2025066497A1Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2024·Application pending·0 cites
- 2488US11697690B2Site-specific glycoengineering of targeting moietiesGENZYME CORP·Filed 2021·Granted Jul 11, 2023·1 cites·20 claims
- 2588US6972319B1Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of useBAYER PHARMACEUTICALS CORP·Filed 2000·Granted Dec 6, 2005·17 cites·5 claims
- 2688US2024182595A1Hyperglycosylated binding polypeptidesGENZYME CORP·Filed 2023·Application pending·0 cites
- 2787US12473356B2scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificityGENZYME CORP·Filed 2024·Granted Nov 18, 2025·0 cites·8 claims
- 2887US10464962B2Oligosaccharide-protein conjugatesGENZYME CORP·Filed 2016·Granted Nov 5, 2019·5 cites·6 claims
- 2987US9441029B2VEGF antagonist compositions and uses thereofSTEFANO JAMES·Filed 2011·Granted Sep 13, 2016·7 cites·32 claims
- 3087US7785580B2Modified IL-4 mutein receptor antagonistsAEROVANCE INC·Filed 2007·Granted Aug 31, 2010·18 cites·17 claims
- 3186US8835614B2Oligosaccharide-protein conjugatesAVILA LUIS Z·Filed 2009·Granted Sep 16, 2014·10 cites·15 claims
- 3286US7507714B2Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of useBAYER CORP·Filed 2004·Granted Mar 24, 2009·14 cites·4 claims
- 3385US10508146B2ScFv-Fc dimers that bind transforming growth factor-BETA1 with high affinity, avidity and specificityGENZYME CORP·Filed 2016·Granted Dec 17, 2019·4 cites·12 claims
- 3484US9493498B2Oligosaccharide-protein conjugatesGENZYME CORP·Filed 2014·Granted Nov 15, 2016·6 cites·14 claims
- 3583US11660328B2GLP-2 analogs and peptibodies for administration before, during or after surgeryTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted May 30, 2023·2 cites·8 claims
- 3681US9096656B2Factor VIII conjugatesBAYER HEALTHCARE LLC·Filed 2013·Granted Aug 4, 2015·4 cites·20 claims
- 3781US2024059793A1Site-specific glycoengineering of targeting moietiesGENZYME CORP·Filed 2023·Application pending·0 cites
- 3881US2024117071A1Site-specific glycoengineering of targeting moietiesGENZYME CORP·Filed 2023·Application pending·0 cites
- 3980US10017573B2Anti-αβTCR antibodySNELL DANIEL·Filed 2012·Granted Jul 10, 2018·8 cites·12 claims
- 4079US12291556B2Parathyroid hormone variantsTAKEDA PHARMACEUTICALS CO·Filed 2023·Granted May 6, 2025·0 cites·17 claims
- 4179US12252504B2Oligosaccharide-protein conjugatesGENZYME CORP·Filed 2022·Granted Mar 18, 2025·0 cites·5 claims
- 4278US11634468B2Parathyroid hormone variantsSHIRE NPS PHARMACEUTICALS INC·Filed 2020·Granted Apr 25, 2023·1 cites·5 claims
- 4376US8440793B2Peptide analogs of alpha-melanocyte stimulating hormonePERRICONE MICHAEL A·Filed 2009·Granted May 14, 2013·4 cites·10 claims
- 4476US2023126645A1Thyroid stimulating hormone compositionsGENZYME CORP·Filed 2022·Application pending·0 cites
- 4575US10385108B2Peptide analogs of alpha-melanocyte stimulating hormoneGENZYME CORP·Filed 2017·Granted Aug 20, 2019·1 cites·20 claims
- 4675US9115174B2Peptide analogs of alpha-melanocyte stimulating hormoneGENZYME CORP·Filed 2013·Granted Aug 25, 2015·2 cites·19 claims
- 4775US7378494B2Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonist peptideBAYER HEALTHCARE AG·Filed 2003·Granted May 27, 2008·11 cites·1 claims
- 4875US2023365954A1Affinity purification of glycoside-cleaving enzymesTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 4972US12503498B2Fc containing polypeptides with altered glycosylation and reduced effector functionGENZYME CORP·Filed 2020·Granted Dec 23, 2025·0 cites·17 claims
- 5072US9708407B2Anti-CD52 antibodiesGENZYME CORP·Filed 2014·Granted Jul 18, 2017·2 cites·45 claims
Showing the top 50 of 90 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Clark Pan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →